Drug Trial Radar · NCT02105272
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
Last checked: Nov 20, 2026Latest source record: Dec 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
237
Actual
Start
Apr 2014
Primary completion
Mar 2015
Study completion Mar 2015
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic solution.
Conditions
- Glaucoma
- Ocular Hypertension
Interventions
OPC-1085EL ophthalmic solutionDrug
Latanoprost ophthalmic solutionDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Decrease From Baseline in Intraocular PressureTime frame: Baseline, week 8 predose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Kansai Region, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.